Routine aspirin benefit queried

The use of ASA in this context is a risk that should have been known to doctors who are required to study pharmacology and physiology.

Longterm use of ASA and even other blood thinning drugs like coumadin may cause destruction of the cell wall membrane leading to a type of free-radical destruction originating from the rupture of cellular lysosomal membranes. Lysosomes are digestive substances found in each cell. They are designed to digest and eliminate waste from the cell. When the membranes are ruptured prematurely, cell contents are digested and destroyed. Silent bleeding and death may ensue.

Omega 3, garlic, cayenne, willow bark, natto or other natural supplements may do as well or better, and without such a high risk of harm.

Routine aspirin benefits queried
Low-dose aspirin should not routinely be used to prevent heart attacks and strokes, contrary to official guidance, say UK researchers.

Analysis of data from over 100,000 clinical trial participants found the risk of harm largely cancelled out the benefits of taking the drug.

Only those who have already had a heart attack or stroke should be advised to take a daily aspirin, they found.

The Lancet study should help clarify a "confusing" issue, GPs said.

The NHS drugs watchdog, the National Institute for health and Clinical Excellence (NICE), has not made a ruling in this area.

But experts in the UK, US and Europe recommend aspirin for people who have not already had a heart attack or stroke, but are at high risk of cardiovascular disease because of factors such as age, blood pressure and cholesterol level.

“ We don't have good evidence that, for healthy people, the benefits of long-term aspirin exceed the risks by an appropriate margin ”
Professor Colin Baigent, study leader

This strategy, known as primary prevention, is based on the result of studies looking at predicted risks and benefits in this population.

But the latest research provides clearer evidence because it is based on data from individuals, the researchers said.

They looked at heart attacks and strokes and major bleeds - a potential side effect of aspirin - in six primary prevention trials, involving 95,000 people at low to average risk and 16 trials involving 17,000 people at high risk - because they had already had a heart attack or stroke.

Use of aspirin in the lower-risk group was found to reduce non-fatal heart attacks by around a fifth, with no difference in the risk of stroke or deaths from vascular causes.

But it also increased the risk of internal bleeding by around a third.

Balance

However, in those patients who had already had a heart attack or stroke and were at risk of having another, the benefits clearly outweighed the chance of adverse events, the researchers said.

Study leader Professor Colin Baigent from the Clinical Trial Service Unit at the University of Oxford, UK, said drug safety was vital when making recommendations that affected tens of millions of healthy people.

"We don't have good evidence that, for healthy people, the benefits of long-term aspirin exceed the risks by an appropriate margin."

He added: "I think the guideline groups will find it useful to have the data analysed in that way."

Professor Steve Field, chair of the Royal College of GPs, said the issue had been confusing for GPs and patients.

"There is no definitive guidance and it makes it bewildering when you have a series of papers which then hint it would be beneficial to take aspirin."

He added that many patients would buy aspirin over the counter - either on the advice of their GP or under their own steam - because it was cheap.

"This important study does suggest people shouldn't take aspirin unless indicated by disease."

Ellen Mason, senior cardiac nurse at the British Heart Foundation said: "It is better for doctors to weigh up the benefit and risk of prescribing aspirin on an individual basis, rather than develop a blanket guideline suggesting everyone at risk of heart disease is routinely given aspirin."

Story from BBC NEWS:
http://news.bbc.co.uk/go/pr/fr/-/2/hi/health/8072215.stm
Published: 2009/05/28 23:11:43 GMT © BBC MMIX

Read more »

Posted in: aspirin,heart attack,natural health news,natural news,stroke

Is there evidence for heart therapy in mainstream medicine?

Worth reading and worth drawing up a list of questions for your provider.

Note that while this article favors use of aspirin, the downside of long term ASA is an issue to question. ASA is something, even in low dose, that over time can cause the cell wall membrane of red blood cells to disintegrate. Natural therapy may include vitamin E, nattokinase, cayenne, garlic (see ALLI-C, right column), or the heart health promoting herb - hawthorne. (More information on these natural treatments may be found here.

Consider as well that there is a great deal of doubt about the veracity of "double blind studies". Most researchers do know that these studies can be manipulated quite easily to get a "desired" result.

A reader poses this query: "I'm intrigued by your comment that "...there is a great deal of doubt about the veracity of 'double blind studies.' Most researchers do know that these studies can be manipulated quite easily to get a 'desired' result.Would you please elaborate? How can these studies be manipulated to get a desired result? Can you provide some examples that are suspicious along those lines?"

The answer is Rosenthal Effect and it is displayed in the film "My Fair Lady". But then money and notoriety, along with the extreme pressure of "publish or perish" are other vectors to be considered.

The Vast Majority of Recommendations Given to Heart Patients Are NOT Supported by Good Science!

Study Questions Evidence Behind Heart Therapies
By Ron Winslow/ WSJ
FEBRUARY 24, 2009

Heart disease is among the most studied illnesses in all of medicine, yet just 11% of more than 2,700 recommendations approved by cardiologists for treating heart patients are supported by high-quality scientific testing, according to new research.

About half the medical recommendations for heart patients have limited scientific backing, according to a study published in Wednesday's Journal of the American Medical Association. Instead, they are based mostly on expert opinion -- subjective viewpoints where consensus is often lacking.

A daily aspirin for heart patients is supported by rigorous scientific research.
For instance, people who previously have had a heart attack and take an aspirin daily to help avert a second such incident can rest assured that the treatment is supported by rigorous scientific studies. But there is much less certainty around another common recommendation that patients treated with artery-opening stents remain on a potent blood thinner for a year to avoid a rare but potentially life-threatening blood clot. The downside: Patients who stay on blood thinners for an extended time risk potential complications if they need urgent surgery.

The findings from the JAMA study reflect the challenge doctors and patients face in choosing the best course of treatment for a variety of conditions. And they underscore that even though drug and device companies, government agencies and philanthropic groups have spent billions of dollars developing and testing new treatments in recent years, much of what happens in the doctor's office or the hospital operating suite might not be based on rigorous scientific evidence.

"In most situations that we encounter when we see patients, it isn't so clear what is the best thing to do," says Pierluigi Tricoci, a cardiologist at Duke University's Duke Clinical Research Institute and lead author of the study.

For more than two decades, health-policy experts, health insurers and employers have been beating the drum for evidence about what works and what doesn't in medicine in an effort to reduce wide variation in medical care, cut health-care costs and develop standards by which to measure the performance of doctors, hospitals and health plans.

This month, the Obama administration and Congress budgeted more than $1 billion of the economic stimulus package to fund research for comparing the effectiveness of different treatments in head-to-head studies aimed at providing evidence to clinicians and insurers on the best treatment strategies.

"We need those studies to make the kind of changes in health care that are being talked about -- being sure we get the best possible care for our patients in the most cost-effective manner," says Sidney Smith, a medical guidelines expert and cardiologist at University of North Carolina, Chapel Hill and senior author of the JAMA paper.

The American College of Cardiology and the American Heart Association have been jointly issuing guidelines to doctors on care of cardiovascular patients for more than 20 years. Recommendations based on multiple randomized clinical trials, in which patients are randomly assigned a treatment, are considered having the highest level of evidence. A single randomized study or non-randomized studies comprise the second level, while recommendations backed by expert opinion or case studies are considered having the weakest evidence. Guidelines are also ranked by whether empirical evidence or general opinion supports that a treatment is useful and effective or not.

For instance, strong evidence of benefit based on several randomized controlled clinical studies is behind guidelines calling for use of aspirin, cholesterol medications called statins and other pills called beta blockers among heart patients to avoid a second heart attack. Similar rigor is behind recommendations that patients who arrive at the emergency room with a major heart attack get treated with an angioplasty balloon within 90 minutes.

Experts Disagree
But such examples are the exception. For a variety of other conditions, treatment recommendations rely largely on non-randomized studies or expert opinion. For instance, it's unclear at what point patients who suffer excess bleeding during a heart procedure should get a blood transfusion, Dr. Tricoci says. And debate rages among cardiologists over two new tools for assessing a patient's long-term risk of a heart attack. When does a blood test for a marker called C-reactive protein aid in making such a prediction? How about a scan to check for calcium buildup in a patient's arteries? Mounting evidence supports each test, but more data are needed to determine how they might best be used, Dr. Tricoci says.

Harlan Krumholz, a cardiologist at Yale University School of Medicine, says doctors should disclose to patients the strength of the evidence behind the care they recommend. "Treatment decisions are often made very dogmatically even when the level of evidence isn't very strong," he says.

One reason for the lack of stronger evidence is that the large "megatrials" that have dominated cardiovascular research in the past decade were sponsored by drug and device companies. While those studies provide an important source of information, they are typically designed primarily to win approval for a treatment or to widen the market for a therapy already on the market, and not to guide treatment decisions, according to the JAMA study.

Limitations of Studies
Clinical studies also typically exclude patients with complicated illness, which can limit the ability of doctors to apply findings to many of their patients. For instance, many heart patients also suffer from kidney disease. But contrast agents typically given to patients undergoing a diagnostic X-ray called cardiac catheterization can be harmful to kidneys.

Dr. Tricoci says he and his colleagues also observed that guideline writers are picked for their expertise in the field -- but they are also often those who consult regularly with industry. Such possible conflict of interest raises the potential to introduce bias into the guidelines, undermining their credibility.

Copyright 2008 Dow Jones & Company, Inc. All Rights Reserved

Read more »

Posted in: 2009,aspirin,heart disease,natural health care,natural health news